Latest filing published 29 Jan 2024 for Recursion Pharmaceuticals, INC., €7,793.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Tina Marriott Larson: trading record in brief
All filings by Tina Marriott Larson on record concern Recursion Pharmaceuticals, Inc., in the capacity of chief executive. We count 58 filings; the first trade dates from 20 April 2021 and the latest from 25 January 2024.
No open-market purchase appears, only 24 sales worth €1.4M. Outside the open market, there are 13 share grants and 19 option exercises. So far in 2024, the count stands at no purchases and 2 sales.
On 29 January 2024 came the latest disclosure, an open-market sale for €76k in Recursion Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Tina Marriott Larson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 8,000 shares@ US$1.061.8% of flowClass A Common StockSEC:0001209191-24-002391:0
- 8,000 shares@ US$1.061.8% of flowClass A Common StockSEC:0001209191-24-000175:0
- 5,378 shares@ US$7.188.1% of flowClass A Common StockSEC:0001209191-23-055846:0
- 3,000 shares@ US$1.060.7% of flowClass A Common StockSEC:0001209191-23-053890:0
- 3,000 shares@ US$1.060.7% of flowClass A Common StockSEC:0001209191-23-051191:0
- 3,000 shares@ US$1.060.7% of flowClass A Common StockSEC:0001209191-23-047538:0
- 5,378 shares@ US$9.1810.4% of flowClass A Common StockSEC:0001209191-23-046426:0
- 8,000 shares@ US$1.061.8% of flowClass A Common StockSEC:0001209191-23-043713:0
- 3,000 shares@ US$1.060.7% of flowClass A Common StockSEC:0001209191-23-040504:0
- 3,000 shares@ US$1.060.7% of flowClass A Common StockSEC:0001209191-23-033974:0
- 5,415 shares@ US$5.606.4% of flowClass A Common StockSEC:0001209191-23-030375:0
- 8,000 shares@ US$1.061.8% of flowClass A Common StockSEC:0001209191-23-013329:0
- 1,603 shares@ US$8.442.9% of flowClass A Common StockSEC:0001209191-23-010781:0
- 217,061 shares0Class A Common StockSEC:0001209191-23-007048:0
- 8,000 shares@ US$1.061.8% of flowClass A Common StockSEC:0001209191-23-005316:0
- 8,000 shares@ US$1.061.8% of flowClass A Common StockSEC:0001209191-22-063013:0
- 1,453 shares@ US$11.863.8% of flowClass A Common StockSEC:0001209191-22-057706:0
- 16,000 shares@ US$1.063.9% of flowClass A Common StockSEC:0001209191-22-054855:0
- 16,000 shares@ US$1.064.0% of flowClass A Common StockSEC:0001209191-22-051979:0
- 1,453 shares@ US$12.964.3% of flowClass A Common StockSEC:0001209191-22-046463:0
- 1,458 shares@ US$5.672.1% of flowClass A Common StockSEC:0001209191-22-030247:0
- 58,500 shares@ US$1.0614.6% of flowClass A Common StockSEC:0001209191-22-017387:0
- 16,000 shares@ US$1.063.9% of flowClass A Common StockSEC:0001209191-22-011969:0
- 4,000 shares@ US$1.061.0% of flowClass A Common StockSEC:0001209191-22-010496:0
- 79,613 shares0Class A Common StockSEC:0001209191-22-007911:0
25 of 27 declarations
